What is the Market's View on Evelo Biosciences Inc (EVLO) Stock's Price and Volume Trends Tuesday?

Evelo Biosciences Inc (EVLO) stock has risen 82.35% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Evelo Biosciences Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on EVLO!

See Full EVLO Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With EVLO Stock Today?

Evelo Biosciences Inc (EVLO) stock has gained 8.4% while the S&P 500 has fallen -0.2% as of 1:39 PM on Tuesday, Nov 21. EVLO has gained $0.05 from the previous closing price of $0.57 on volume of 813,770 shares. Over the past year the S&P 500 has risen 14.90% while EVLO has fallen -98.33%. EVLO lost -$13.34 per share in the over the last 12 months.

More About Evelo Biosciences Inc

Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer. Click Here to get the full Stock Report for Evelo Biosciences Inc stock.